Bruce A Ellsworth

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi request reprint Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
  2. ncbi request reprint Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series
    Bruce A Ellsworth
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, PO Box 5400 Princeton, NJ 08543, USA
    Bioorg Med Chem Lett 17:3978-82. 2007
  3. ncbi request reprint Remarkable beta-selectivity in the synthesis of beta-1-C-arylglucosides: stereoselective reduction of acetyl-protected methyl 1-C-arylglucosides without acetoxy-group participation
    Prashant P Deshpande
    Process Research and Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, USA
    J Org Chem 72:9746-9. 2007
  4. doi request reprint Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383
    Doree F Sitkoff
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 5400, USA
    Eur J Pharmacol 651:9-17. 2011
  5. doi request reprint Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
    Bruce A Ellsworth
    Research and Development, Bristol Myers Squibb Co, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 18:4770-3. 2008

Collaborators

Detail Information

Publications5

  1. doi request reprint Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
    ..These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes...
  2. ncbi request reprint Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series
    Bruce A Ellsworth
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, PO Box 5400 Princeton, NJ 08543, USA
    Bioorg Med Chem Lett 17:3978-82. 2007
    ..Compound 35 elicits a 46% reduction in food intake in ad libidum fed rats 4-h post-dose...
  3. ncbi request reprint Remarkable beta-selectivity in the synthesis of beta-1-C-arylglucosides: stereoselective reduction of acetyl-protected methyl 1-C-arylglucosides without acetoxy-group participation
    Prashant P Deshpande
    Process Research and Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, USA
    J Org Chem 72:9746-9. 2007
    ..By changing from the usual benzyl ether protecting groups because of cost and chemical compatibility concerns, the new process is made additionally efficient and highly selective...
  4. doi request reprint Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383
    Doree F Sitkoff
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 5400, USA
    Eur J Pharmacol 651:9-17. 2011
    ....
  5. doi request reprint Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
    Bruce A Ellsworth
    Research and Development, Bristol Myers Squibb Co, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 18:4770-3. 2008
    ..The lead C-arylglucoside (7a) demonstrates superior metabolic stability to its O-arylglucoside counterpart (4) and it promotes glucosuria when administered in vivo...